HONOLULU, Jan. 28 /PRNewswire/ -- Tissue Genesis, Inc., an emerging leader in advanced tissue engineering and cell therapy solutions, and American Medical Systems Holdings, Inc. announced today they have signed an agreement for the research and development of adipose (fat)-derived regenerative cells for use in treating pelvic health disorders. American Medical Systems will pay $1.1 million over the life of the agreement to obtain rights offered by Tissue Genesis, Inc.
“We are proud to partner with American Medical Systems - a company with true vision and initiative - as they recognize the immense potential benefits of cell therapy,” said Anton Krucky, President and CEO of Tissue Genesis. “Adipose tissue is a rich source of regenerative cells - including adult stem cells - and these cells have shown promising results in their ability to help patients. American Medical Systems’ world-class technology and business acumen will be a tremendous asset to Tissue Genesis.”
The Tissue Genesis Cell Isolation System processes a small amount of the patient’s own adipose tissue into a concentration of millions of regenerative cells, including adult stem cells, microvascular endothelial cells, and other cells. These cells can be coated onto artificial implants or directly injected into damaged tissue, to improve circulation and support the formation of new tissue. The Cell Isolation System conveniently brings cell therapy solutions right to a patient’s bedside, as it completes the process in about an hour - in the operating room - while the surgeon prepares the patient to receive his or her own cells back into the damaged area.
Dr. Stuart Williams, Chief Science Officer of Tissue Genesis, and a pioneer of adipose-derived cell technology, said: “The addition of American Medical Systems to the companies and institutions working on Tissue Genesis’ regenerative cell technology will significantly extend our advancement in this market. This collaboration has the potential to propel both companies into the next generation of regenerative healthcare.”
Tissue Genesis Safe Harbor Statement
This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Tissue Genesis, Inc., and members of its management as well as the assumptions on which such statements are based. There can be no assurance that Tissue Genesis will be able to commercially develop its therapeutic cell technology or products, that necessary regulatory approvals will be obtained, that any clinical trials will be successful, or that the proposed treatments will prove to be safe and/or effective. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Tissue Genesis, Inc.
